Microsoft selects Marvell LiquidSecurity for Azure Cloud HSM service
Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), a $13.7 billion market cap company with an impressive 89% gross profit margin and perfect Piotroski Score of 9, recently executed a series of stock transactions. According to an SEC filing, Benkowitz sold shares amounting to approximately $640,183. The sale took place on March 10, 2025, with prices per share ranging from $313.93 to $323.99. These transactions were conducted as part of a Rule 10b5-1 trading plan. After these sales, Benkowitz’s trust no longer holds any shares directly. InvestingPro analysis shows the company maintains excellent financial health with strong fundamentals.
In addition to the sales, Benkowitz also acquired 2,000 shares through the exercise of stock options at a price of $111.00 per share, valued at $222,000. These shares were subsequently sold as part of the transactions mentioned above. Trading at a P/E ratio of 11.6, InvestingPro analysis indicates the stock is currently undervalued, with 13 additional ProTips available for subscribers.
In other recent news, United Therapeutics Corporation reported its fourth-quarter 2024 earnings, which revealed a shortfall in both earnings per share (EPS) and revenue projections. The company posted an EPS of $6.19, below the anticipated $6.68, while revenue reached $735.9 million, slightly under the forecasted $739.92 million. Despite this miss, United Therapeutics achieved record annual revenue growth for the third consecutive year, with a 24% increase over 2023. Key products like Tyvaso and Orenitram showed strong revenue growth, with Tyvaso increasing by 19% and Orenitram by 28%.
Additionally, Goldman Sachs analyst Chris Shibutani revised the price target for United Therapeutics stock to $293 from $302, maintaining a Neutral rating. This adjustment was influenced by a modest reduction in Tyvaso forecasts and increased research and development spending. Shibutani noted that Tyvaso missed expectations, facing challenges from contracting efforts and anticipated competition from Yutrepia by LQDA™ in 2025. Despite these challenges, United Therapeutics continues to advance its pipeline with significant clinical trial progress, including the anticipated first UKidney transplant around mid-2025.
The company’s management remains optimistic about long-term growth, emphasizing continued double-digit revenue growth into the mid-decade. United Therapeutics did not provide financial guidance, consistent with their standard practice, and while further share repurchases could occur, there were no announcements regarding additional plans.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.